XML 78 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 24, 2018
USD ($)
Sep. 30, 2019
USD ($)
ft²
Jun. 30, 2019
USD ($)
ft²
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Nov. 30, 2016
Term
Jul. 31, 2015
May 31, 2013
ft²
Sep. 30, 2019
USD ($)
ft²
Sep. 30, 2019
USD ($)
ft²
Jan. 01, 2019
USD ($)
Dec. 31, 2018
Commitment And Contingencies [Line Items]                        
Right-of-use assets   $ 8,618,000             $ 8,618,000 $ 8,618,000 $ 6,600,000  
Operating lease liabilities                     $ 7,000,000.0  
Operating lease, straight-line cost                 $ 567,000 1,398,000    
GeneQuine Biotherapeutics GmbH ("GeneQuine") [Member] | Definitive Agreement [Member]                        
Commitment And Contingencies [Line Items]                        
License agreement, upfront fee paid       $ 2,000,000.0                
Milestone, Revenue recognized                   0    
Research and development milestone payment $ 750,000                      
GeneQuine Biotherapeutics GmbH ("GeneQuine") [Member] | Definitive Agreement [Member] | Investigational New Drug (IND) [Member]                        
Commitment And Contingencies [Line Items]                        
Research and development milestone payment       750,000                
GeneQuine Biotherapeutics GmbH ("GeneQuine") [Member] | Definitive Agreement [Member] | Maximum [Member]                        
Commitment And Contingencies [Line Items]                        
Additional milestone payments       54,000,000.0                
Xenon Pharmaceuticals, Inc. ("Xenon") [Member] | Definitive Agreement [Member]                        
Commitment And Contingencies [Line Items]                        
License agreement, upfront fee paid   3,000,000.0                    
Milestone, Revenue recognized                   $ 0    
Xenon Pharmaceuticals, Inc. ("Xenon") [Member] | Definitive Agreement [Member] | Sales Related Milestone Payments [Member]                        
Commitment And Contingencies [Line Items]                        
Additional milestone payments   75,000,000.0                    
Xenon Pharmaceuticals, Inc. ("Xenon") [Member] | Definitive Agreement [Member] | Maximum [Member]                        
Commitment And Contingencies [Line Items]                        
Additional milestone payments   $ 40,800,000                    
Evonik Corporation [Member]                        
Commitment And Contingencies [Line Items]                        
Supply agreement period           5 years            
Supply agreement renewal term           2 years            
Number of renewal terms | Term           2            
Supply agreement description                   The Supply Agreement will renew for two successive two year terms upon mutual written consent by both parties.    
Manufacturing and Supply Agreement with Patheon UK Limited [Member]                        
Commitment And Contingencies [Line Items]                        
Operating lease, discount rate     6.10%                  
Operating lease, remaining lease term   8 years 1 month 6 days             8 years 1 month 6 days 8 years 1 month 6 days    
Operating lease, straight-line cost                 $ 54,000 $ 147,000    
Manufacturing agreement period             10 years          
Increase in operating lease liability     $ 500,000                  
Increase in right of use asset     $ 500,000                  
Phase 2 Proof of Concept (PoC) Clinical Trial [Member] | GeneQuine Biotherapeutics GmbH ("GeneQuine") [Member] | Definitive Agreement [Member] | Maximum [Member]                        
Commitment And Contingencies [Line Items]                        
Additional milestone payments       $ 8,700,000                
Phase 2 Proof of Concept (PoC) Clinical Trial [Member] | Xenon Pharmaceuticals, Inc. ("Xenon") [Member] | Definitive Agreement [Member] | Maximum [Member]                        
Commitment And Contingencies [Line Items]                        
Additional milestone payments   $ 9,000,000.0                    
Burlington Massachusetts [Member]                        
Commitment And Contingencies [Line Items]                        
Operating lease office space | ft²   41,873           36,500 41,873 41,873    
Lease termination date               Oct. 31, 2023   Apr. 30, 2025    
Operating lease, discount rate   6.80%             6.80% 6.80%   8.90%
Operating lease, remaining lease term   5 years 7 months 6 days             5 years 7 months 6 days 5 years 7 months 6 days   4 years 9 months 18 days
Additional leased office space | ft²     5,330                  
Minimum monthly lease payments                   $ 108,000    
Lease commencement date for additional space                   Jul. 01, 2019    
Right-of-use assets   $ 2,500             $ 2,500 $ 2,500    
Operating lease liabilities   $ 2,500             2,500 2,500    
Operating lease, straight-line cost                 $ 500,000 $ 1,100,000    
Lessee, operating lease, extension term   18 months             18 months 18 months    
Woburn, Massachusetts [Member]                        
Commitment And Contingencies [Line Items]                        
Operating lease, discount rate                       8.40%
Operating lease, remaining lease term   2 years 4 months 24 days             2 years 4 months 24 days 2 years 4 months 24 days   3 years 2 months 12 days
Operating lease, straight-line cost                 $ 46,000 $ 139,000    
Operating lease term         5 years              
Monthly lease payment         $ 15,000              
Operating lease, option to extend                   The Woburn lease includes an option to extend the term of the lease for two years.